Navigation Links
Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
Date:4/29/2008

howed onset of effect as early as 2 minutes after dosing with AZ-007.

There were no serious adverse events. The most frequently reported adverse events in subjects receiving AZ-007 were dizziness and somnolence. These data indicate a rapid onset of effect, apparently directly related to the IV-like pharmacokinetics, and showed that AZ-007 was generally safe and well tolerated in this population of healthy volunteers.

About Insomnia

Insomnia is a prevalent disorder that drives a multi-billion dollar market of prescription medications each year. An estimated 10 to 30% of the U.S. population experiences either chronic or occasional insomnia. In 2005, one survey conducted by the National Sleep Foundation showed that 54% of the respondents experienced a minimum of one symptom of insomnia at least a few nights a week. Of those, respondents complained primarily of waking up feeling unrefreshed (38%), waking up frequently during the night (32%), having difficulty falling asleep (21%), and waking up too early and not being able to get back to sleep (21%). There is a potentially significant clinical need for rapid and predictable onset of sleep in patients with insomnia, as well as a predictable duration of sleep and rapid, clear awakening.

About AZ-007 (Staccato zaleplon)

AZ-007 is the combination of Alexza's proprietary Staccato system with zaleplon, a drug belonging to the class of compounds known generally as hypnotics. The Staccato system technology is a hand-held, chemically-heated, single dose inhaler designed to generate and deliver excipient-free drug aerosol for deep lung delivery that results in IV-like pharmacokinetics.

The Company believes that AZ-007 may provide rapid sleep onset. Moreover, by coupling the shorter half-life of zaleplon with the lower dose enabled by the Staccato system technology, the overall product profile may match well with an unmet clinical need for patients with insomnia.

About Alexza Pharma
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron Pharmaceuticals, ... SAN and NYSE: SNY ) today announced ... in people with hypercholesterolemia met their primary efficacy endpoint ... lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo ... targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... VEGAS , July 30, 2014  DigiPath, Inc. ... that is expanding into the cannabis testing and education ... in its business and affairs not previously disclosed or, ... the recent unusual market action. "We have ... over the last three trading days," said Steve ...
(Date:7/30/2014)... PHILADELPHIA , July 30, 2014  Packaging Coordinators, ... a definitive agreement to acquire Penn Pharmaceutical Services Limited ... Wales in the United Kingdom ... New Hope, Pennsylvania and Tokyo ... manufacturing services, including Clinical and Commercial dosage form manufacturing, ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
... Nov. 10, 2010 SCOLR Pharma, Inc. (NYSE AMEX: ... and nine months ended September 30, 2010.Stephen J. Turner, SCOLR ... of the year will be to continue executing the plans ... which have both been advanced in the last quarter. ...
... Nov. 10, 2010 The Halifax Health - Betty ... celebrated the beginning of a new decade of caring ... during a ceremony held this afternoon in Daytona Beach, ... and Halifax Health will celebrate the 10th anniversary of ...
Cached Medicine Technology:SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 7Speediatrics Unit Celebrates 10th Anniversary 2Speediatrics Unit Celebrates 10th Anniversary 3
(Date:7/31/2014)... “Bivalent, Heteronomy and Natural Killer Cells?” opened ... bands ~ homeostatic CS science is the answer.” , ... new on the Bryan William Brickner Blog, ten ... cannabinoid system (CS). The line-up links to PubMed articles ... directly on homeostasis, two each on the central nervous, ...
(Date:7/31/2014)... In its latest blog post, Best ... having family close by during a stay in rehab can ... is successful, is focusing on nine secrets that addicts don’t ... that they can spot an addict from a mile away, ... best Drug Rehabilitation’s CEO Per Wickstrom . “However, take ...
(Date:7/31/2014)... 2014 Continuing Education Company Inc ... Clinical Issues in Primary Care Continuing Medical ... at the Wailea Beach Marriott Resort and Spa on ... been developed for today's Primary Care practitioners. In 5 ... says Barbara Lyons, VP Education. , The agenda for ...
(Date:7/30/2014)... Denver, Colorado (PRWEB) July 30, 2014 ... the skiers wearing orange vests emblazoned with “Blind Skier.” ... Colorado slopes through Foresight Ski Guides , a ... with visually impaired and blind participants (VIPs) for snow ... interested in guiding can learn more and pick up ...
(Date:7/30/2014)... DC (PRWEB) July 31, 2014 ... health care environment more responsive to an increasingly ... years of experience and scholarly expertise to the ... the health care professions: "Diversity and Cultural Competence ... 2013). Janice L. Dreachslin, PhD, a professor in ...
Breaking Medicine News(10 mins):Health News:Homeostatic Cannabinoid Science ~ Publius’ July Roundup on the Bryan William Brickner Blog 2Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 2Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 3Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 2Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 3Health News:Colorado Non-Profit Foresight Ski Guides Seeking Applications for Blind and Visually Impaired Skiers and Guides for Vail Ski Season 2Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 2Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 3
... Chase, MD Postmenopausal women who have higher testosterone levels ... resistance and the metabolic syndrome compared to women with ... for publication in The Endocrine Society,s Journal of ... is an important step, say researchers, in understanding the ...
... ... and Total Health the all-natural herbal Nutraceutical Company together for the health of our ... ... Association and Registry (ACTHA) announced today that Total Health Enhancement Corp. ...
... ... Scrubs& Beyond shipped directly to their home or work! , ... Brentwood, MO (PRWEB) November 4, 2009 -- Medical professionals ... to their home or work! Orders will ship via SmartPost, which is a collaboration between ...
... Due to the increasing complexities of treating digestive diseases, ... enhanced abilities and experiences in specific disease areas or ... to a "Report of the Multisociety Task Force on ... the achievements of trainees based on specific defined competencies ...
... Nov. 3 Robbins & Myers, Inc. (NYSE: RBN ... Annual Industrial Conference on November 11, 2009. Representing the ... Officer, and Christopher M. Hix, Vice President and Chief Financial ... from 8:20-8:50 a.m., CT, at the Four Seasons Hotel in ...
... of Hematology (ASH) is honoring two prominent hematologists with ASH ... in the training and career development of hematologists early in ... MD, will receive their awards during the 51st ASH Annual ... receiving the Mentor Award for Basic Science, is the David ...
Cached Medicine News:Health News:Postmenopausal women with higher testosterone levels 2Health News:American Competitive Trail Horse Association Announces Total Health Enhancement Corp. as a Sponsor Member 2Health News:Smart Post Brings Scrubs & Beyond to Canadian Doorsteps 2Health News:Gastroenterology/hepatology societies release report evaluating fellowship training curriculum 2Health News:Gastroenterology/hepatology societies release report evaluating fellowship training curriculum 3Health News:The American Society of Hematology to honor inspirational hematologists with Mentor Awards 2